236 
Market Cap
As of February 26, 2012: $175,653,000.00
Stock Chart
Prima Biomed - 30 Day Poll
Recent BLOGS About Prima Biomed Add New
There are no blogs to display.
Latest Company News
|
Prima BioMed to Present at the 37th Annual Deutsche Health Care Conference
MarketWatch (press release) - May 3, 2012 SYDNEY, AUSTRALIA, May 03, 2012 (MARKETWIRE via COMTEX) -- Prima BioMed Ltd (NASDAQ:PBMD) (asx:PRR) announced today that Dr. Neil Frazer, Chief Medical Officer, will present at the Deutsche Health Care Conference on Tuesday, May 8, 2012 at 8:40am ...
|
|
Midday: Aus shares reverse gains
Finance News Network - May 2, 2012 Buoyed by positive offshore leads, on the back of strong US and Chinese manufacturing data, the Australian share market rose at open but reversed gains and is trading flat noon.
|
|
Volatile royalties often bitter pills for biotechs
Brisbane Times - Apr 29, 2012 This much was clear in the wake of last week's column focusing on the market's valuation of cancer therapy developer Prima BioMed (ASX: PRR).
|
|
Volatile royalties often bitter pills for biotechs
BusinessDay.com.au - Apr 29, 2012 This much was clear in the wake of last week's column focusing on the market's valuation of cancer therapy developer Prima BioMed (ASX: PRR).
|
|
Volatile royalties often bitter pills for biotechs
Sydney Morning Herald - Apr 29, 2012 PASSIONS run high in the biotech world. This much was clear in the wake of last week's column focusing on the market's valuation of cancer therapy developer Prima BioMed (ASX: PRR).
|
|
Prima BioMed Announces Quarterly Activity Report for Quarter ending 31 March 2012
SYS-CON Media (press release) - Apr 27, 2012 By Marketwire . SYDNEY, AUSTRALIA -- (Marketwire) -- 04/27/12 -- Prima BioMed (Prima) (ASX: PRR) (NASDAQ: PBMD) today released its Appendix 4C - Quarterly Report for the three month period ending 31 March 2012.
|
Website
Videos related to Prima Biomed
Company Profile
The company has 3 programs in place.
The lead program, CVacTM has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. The CVac product consists of an adjuvant, attached to a tumour cell surface protein. The treatment is patient-specific and delivered to patients via dendritic cell therapy i.e.patient’s dendritic cells are isolated from their blood & surface protein is mixed with the cells to introduce the protein so it is expressed on the surface of the cells. Cells are then re-introduced to the patient. A successful phase I trial was completed which examined the safety of the product in patients with adenocarcinomas. All patients produced an immune response to the product. The phase IIa clinical trial to determine clinical activity in ovarian cancer announced evidence of clinical activity in response to CVacTM therapy. CVacTM demonstrated a positive clinical response or stabilisation of disease in four of the twenty-one patients.
The second program is focussing on the identification of an antibody to tumour cell target, cripto-1. This program has been partnered with Medarex Inc. (see our USA sister website).
The third is focussing on the development of an adjuvant in Cancer & infectious disease vaccines. It could be coupled to a variety of antigens from viruses, bacteria or parasites to induce a protective immune responses (antibody and T cells). Biological proof of principal has been achieved and early product development has commenced.
Finances
The lead program, CVacTM has completed Phase IIa clinical trials and focuses on the development of an ex vivo immunotherapy for ovarian cancer. The CVac product consists of an adjuvant, attached to a tumour cell surface protein. The treatment is patient-specific and delivered to patients via dendritic cell therapy i.e.patient’s dendritic cells are isolated from their blood & surface protein is mixed with the cells to introduce the protein so it is expressed on the surface of the cells. Cells are then re-introduced to the patient. A successful phase I trial was completed which examined the safety of the product in patients with adenocarcinomas. All patients produced an immune response to the product. The phase IIa clinical trial to determine clinical activity in ovarian cancer announced evidence of clinical activity in response to CVacTM therapy. CVacTM demonstrated a positive clinical response or stabilisation of disease in four of the twenty-one patients.
The second program is focussing on the identification of an antibody to tumour cell target, cripto-1. This program has been partnered with Medarex Inc. (see our USA sister website).
The third is focussing on the development of an adjuvant in Cancer & infectious disease vaccines. It could be coupled to a variety of antigens from viruses, bacteria or parasites to induce a protective immune responses (antibody and T cells). Biological proof of principal has been achieved and early product development has commenced.
Finances
Prima Biomed reported negative cash flow of $4.82m for quarter ended 30 September 2011. Operating cash flow for the period was $(5.26m). Investing cash flow was $(129,000). Financing cash flow was $569,000. Cash in hand at the end of the quarter was $51.11m.
Of Note:
Dendreon is a similar company in terms of technological apporach and has done well so far re prostate cancer - see our sister USA website
Dendreon is a similar company in terms of technological apporach and has done well so far re prostate cancer - see our sister USA website
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use